If in the US the Food and drug administration has spoken out against the third dose of Covid vaccine (with the exception of over 65s and high risk individuals) why Pfizer did not provide enough security data, numbers coming in from Israel they are comforting about the role of the third injection in protecting against contagion. A study published in the New England Journal of Medicine, on the basis of data from the Israeli ministry of health, shows that the cases of contagion and serious illness drop “substantially” with the third Pfizer dose administered so far to over 3 million people.
The infection rate, detected at least 12 days after the ‘booster’, is “11.3 times” lower than the two doses while the severe disease rate is less than 19.5 ″ times. The study was conducted from July 30 to August 31 on 1.13 million over 60 who had completed immunization 5 months earlier, divided into two groups: those who received the third dose and those who received two.
Data released in the United States since Center for Disease Control and Prevention, as the New York Times, they say instead that the effectiveness of the Pfizer-BioNTech vaccine against Covid hospitalizations drops significantly four months after the second dose. According to the CDC Pfizer is 91% effective in preventing hospitalizations up to 4 months after the second dose, then the effectiveness drops to 77%. Data relating to Modern instead they show how that vaccine remains effective against hospitalizations even after four months: the effectiveness after four months against hospitalizations is 92%, virtually identical to the initial 93%. The study is based on the analysis of 3,700 adults hospitalized in the United States between March and August. For Johnson & Johnson, however, there are no comparable data as the sample examined did not include enough people who had received the single J&J dose. According to the New York Times, the CDC data contrast with other studies according to which the efficacy of the Pfizer vaccine against hospitalizations remains above 90% despite the variant. Delta.
Support ilfattoquotidiano.it: if you believe in our battles, fight with us!
Supporting ilfattoquotidiano.it means two things: allowing us to continue publishing an online newspaper full of news and insights, free for all. But also to be an active part of a community and to do one’s part to carry on together the battles we believe in with ideas, testimonies and participation. Your contribution is essential. Support now